On Apr. 13, 2022, the U.S. Food and Drug Administration (FDA) announced that the legislation clarifying the agency…
On Apr. 7, 2022, Moderna and IAVI announced a collaboration to employ mRNA technology to meet the challenge…
On Apr. 6, 2022, a new study in the Journal of Clinical Oncology showed that women receiving certain…
On Apr. 1, 2022, the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance (SCCA) announced a…
On Apr. 1, 2022, Merck and Ridgeback Biotherapeutics announced data evaluating LAGEVRIO (molnupiravir), an investigational oral antiviral COVID-19…
On Mar. 31, 2022, researchers in Brazil reported that a study of COVID-19 patients at 12 clinics that…
On Mar. 31, 2022, Sorrento Therapeutics announced that the U.S. Food and Drug Administration (FDA) had given clearance to…
On Mar. 31, 2022, researchers announced they have created a complete, gap-free sequence of the roughly 3 billion…
On Mar. 29, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) had expanded…
On Mar. 25, 2022, GlaxoSmithKline and Vir Biotechnology announced that the US Food and Drug Administration (FDA) had…
On Mar. 25, 2022, the WHO and the Government of India signed an agreement to establish the WHO…
On Mar. 22, 2022, Pfizer announced an agreement with UNICEF to supply up to 4 million treatment courses…
On Mar. 22, 2022, Windtree Therapeutics announced results from its Phase 2 study of lucinactant (KL4 surfactant) for…
On Mar. 21, 2022, Twist Bioscience announced the launch of specific synthetic RNA positive controls for SARS-CoV-2 encapsulated…
On Mar. 17, 2022, the National Institutes of Health announced that nearly 100,000 highly diverse whole genome sequences…
On Mar. 17, 2022, Soligenix announced the results of a booster vaccination study using CiVax™ (heat stable COVID-19…
On Mar. 10, 2022, Cocrystal Pharma announced dosing of the first subjects in a Phase 1 clinical trial…
On Mar. 10, 2022, schools with mandatory masking during the Delta surge had approximately 72% fewer cases of…
On Mar. 9, 2022, Pfizer announced that it had initiated a Phase 2/3 study, EPIC-PEDS (Evaluation of Protease…
On Mar. 4, 2022, the U.S. Centers for Disease Control and Prevention (CDC) reported that COVID-19 vaccination coverage with…
On Mar. 3, 2022, the World Health Organization (WHO) and the Medicines Patent Pool (MPP) jointly welcomed the announcement…
On Mar. 3, 2022, a study carried out in southwestern Ontario identified a highly mutated variant of SARS-CoV-2…
On Mar. 2, 2022, Roche announced an initial donation of essential medicines to Ukraine. Roche is working diligently…
On Mar. 2, 2022, the Iowa Department of Agriculture and Land Stewardship and the United States Department of…
On Mar. 2, 2022, Sorrento Therapeutics announced that its Phase I study of intranasal (IN) STI-9199 (COVISHIELDTM IN) has…
On Feb. 28, 2022, the Patent and Trial Appeal Board of the U.S. Patent and Trademark Office (USPTO)…
On Feb. 22, 2022, Sorrento Therapeutics announced that additional preclinical results demonstrate broad spectrum COVISHIELD (STI-9167) neutralizing activity…
On Feb. 1, 2022, University of Virginia Cancer Center announced it had been awarded a Comprehensive Cancer Center…
On Feb. 17, 2022, after studying blood samples from 244 patients hospitalized for COVID-19, a group of researchers,…
On Feb. 17, 2022, Resverlogix announced that the first Brazilian site had been initiated for its Phase 2b…